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EDITORIAL
Randomized Controlled Trial of Resection Versus
Radiotherapy after Induction Chemotherapy in Stage
IIIA-N2 Non-small Cell Lung Cancer
Johan Vansteenkiste, MD, PhD,* Daniel Betticher, MD, PhD,† Wilfried Eberhardt, MD,‡
and Paul De Leyn, MD, PhD§
A recent article in the Journal of the National Cancer Institute presented results of theEORTC 08941 study.1 The main conclusion was that surgical (i.e., chemotherapy and
surgical resection) and non-surgical multimodality treatments (chemotherapy and radio-
therapy) led to similar 5-year survival rates of approximately 15% among selected patients
with stage IIIA-N2 non-small cell lung cancer (NSCLC) with response to induction
chemotherapy.
This important study must be understood in its appropriate context of patients with
unresectable IIIA-N2 disease: induction chemotherapy did not convert unresectable
disease into resectable—as illustrated by the 50% incomplete resection rate in the surgery
arm—and, not unexpectedly, did not result in better outcome compared with radiotherapy.
The crucial term “unresectable” was not clearly defined in the article. In the initial
protocol (October 15, 1994), patients were eligible if “judged by the responsible surgeon
to have irresectable N2-disease.” This vital criterion was amended to the “guidelines for
irresectability” as they are mentioned in the publication on page 443, by an amendment
on September 15, 2000. Consequently, proper guidelines for irresectability were in place
only in the final part of the recruitment (September 2000 until December 2002).
Another concern is how the assessment of irresectability was performed. This is a
complex multidisciplinary process. This had to be “judged by an experienced thoracic
surgeon,” but there were 23 centers that randomized 1% of the patients. Was a
multidisciplinary team with sufficient expertise in assessing resectability in N2 disease
available?
Different European series with dedicated assessment of resectability point at
remarkably similar 5-year survival rates of 36% (Swiss group),2 34% (Essen group),3 or
30% (Leuven group)4 among patients with IIIA-N2 disease with resection after induction
treatment. Even if non randomized, all were well-designed prospective trials, with
intent-to-treat reporting and reliable long-term follow-up. In the randomized US Inter-
group data, 5-year survival again was 36%, if the mortality of pneumonectomy could be
avoided.5 The rationale of these studies is to provide surgery as the best local treatment
for resectable NSCLC and improve outcome by induction therapy to manage distant
micrometastasis. In this respect, it is noteworthy that, in the EORTC experience, surgery
provided better local control (32% locoregional failure) than radiotherapy (55%).
The hypothesis of EORTC 08941 that surgery might improve the prognosis of
unresectable N2 disease if performed after induction chemotherapy unfortunately did
not become reality, so that chemoradiotherapy remains standard for this group.
However, this should not lead to the over-interpretation this is the best choice for
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every patient with IIIA-N2 NSCLC. We concur with the
editorial that patients who are good candidates for surgery
may still be appropriately managed by using resection
rather than radiation.6 We should continue to pursue further
improvement in the current 5-year survival prospects of
approximately 30% with surgical multimodality treatment for
resectable N2, by integration of modern techniques such as
positron emission tomography-computed tomography, video-
mediastinoscopy, and ultrasound-guided endoscopy into a
truly multidisciplinary process of staging and assessment of
resectability.7,8 Furthermore, answers from ongoing trials on
the question whether modern chemoradiotherapy induction
may be superior to chemotherapy are eagerly awaited.
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